See more : COG Financial Services Limited (COG.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Incyte Corporation (INCY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Incyte Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Yangarra Resources Ltd. (YGRAF) Income Statement Analysis – Financial Results
- ShinWon Corporation (009270.KS) Income Statement Analysis – Financial Results
- Daios Plastics S.A. (DAIOS.AT) Income Statement Analysis – Financial Results
- Trans Freight Containers Limited (TRANSFRE.BO) Income Statement Analysis – Financial Results
- Daitobo Co., Ltd. (3202.T) Income Statement Analysis – Financial Results
Incyte Corporation (INCY)
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.70B | 3.39B | 2.99B | 2.67B | 2.16B | 1.88B | 1.54B | 1.11B | 753.75M | 511.50M | 354.95M | 297.06M | 94.46M | 169.88M | 9.27M | 3.92M | 34.44M | 27.64M | 7.85M | 14.15M | 47.09M | 101.61M | 219.26M | 194.17M | 157.00M | 134.80M | 88.40M | 41.80M | 12.20M | 200.00K | 300.00K |
| Cost of Revenue | 255.00M | 207.00M | 150.99M | 131.33M | 114.25M | 94.12M | 79.48M | 58.19M | 26.97M | 3.00M | 630.00K | 157.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -34.84M | -24.70M | -17.80M | -10.40M | -6.50M | -2.60M | -900.00K | 3.60M |
| Gross Profit | 3.44B | 3.19B | 2.84B | 2.54B | 2.04B | 1.79B | 1.46B | 1.05B | 726.78M | 508.49M | 354.32M | 296.90M | 94.46M | 169.88M | 9.27M | 3.92M | 34.44M | 27.64M | 7.85M | 14.15M | 47.09M | 101.61M | 219.26M | 229.01M | 181.70M | 152.60M | 98.80M | 48.30M | 14.80M | 1.10M | -3.30M |
| Gross Profit Ratio | 93.10% | 93.90% | 94.94% | 95.08% | 94.71% | 95.00% | 94.83% | 94.74% | 96.42% | 99.41% | 99.82% | 99.95% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 117.94% | 115.73% | 113.20% | 111.76% | 115.55% | 121.31% | 550.00% | -1,100.00% |
| Research & Development | 1.63B | 1.59B | 1.46B | 2.22B | 1.15B | 1.20B | 1.33B | 581.86M | 479.51M | 347.52M | 260.44M | 210.39M | 178.71M | 123.88M | 119.44M | 146.36M | 104.89M | 87.60M | 95.62M | 88.27M | 116.25M | 152.37M | 213.34M | 192.56M | 146.80M | 97.20M | 68.90M | 40.90M | 19.30M | 0.00 | 0.00 |
| General & Administrative | 1.16B | 1.00B | 739.60M | 516.90M | 453.41M | 434.41M | 366.41M | 303.25M | 196.61M | 165.77M | 109.98M | 85.36M | 58.22M | 32.33M | 27.58M | 17.07M | 15.24M | 16.91M | 13.01M | 74.73M | 30.33M | 47.15M | 70.63M | 64.20M | 37.20M | 25.40M | 12.10M | 6.80M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 40.00K | -40.00K | 22.00K | 15.30M | 10.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.16B | 1.00B | 739.56M | 516.92M | 468.71M | 434.41M | 366.41M | 303.25M | 196.61M | 165.77M | 109.98M | 85.36M | 58.22M | 32.33M | 27.58M | 17.07M | 15.24M | 16.91M | 13.01M | 74.73M | 30.33M | 47.15M | 70.63M | 64.20M | 37.20M | 25.40M | 12.10M | 6.80M | 3.90M | 12.30M | 1.20M |
| Other Expenses | 31.23M | 7.97M | 37.02M | 42.80M | 52.18M | 31.76M | 7.70M | 17.42M | 0.00 | 0.00 | 0.00 | 0.00 | 712.00K | -379.00K | 2.01M | -227.00K | -407.00K | 0.00 | 0.00 | 0.00 | 15.87M | 0.00 | 0.00 | 34.84M | 24.70M | 17.80M | 10.40M | 6.50M | 6.50M | 13.20M | 1.60M |
| Operating Expenses | 2.82B | 2.60B | 2.23B | 2.78B | 1.62B | 1.63B | 1.69B | 885.11M | 676.13M | 513.30M | 370.42M | 295.75M | 237.64M | 155.83M | 149.03M | 163.21M | 119.72M | 104.51M | 108.63M | 163.00M | 162.44M | 199.52M | 283.96M | 291.60M | 208.70M | 140.40M | 91.40M | 54.20M | 25.80M | 13.20M | 1.60M |
| Cost & Expenses | 3.08B | 2.80B | 2.39B | 2.91B | 1.74B | 1.73B | 1.77B | 943.30M | 703.10M | 516.30M | 371.05M | 295.91M | 237.64M | 155.83M | 149.03M | 163.21M | 119.72M | 104.51M | 108.63M | 163.00M | 162.44M | 199.52M | 283.96M | 256.76M | 184.00M | 122.60M | 81.00M | 47.70M | 23.20M | 12.30M | 5.20M |
| Interest Income | 172.35M | 39.93M | 10.65M | 2.17M | 1.86M | 0.00 | 17.50M | 4.41M | 7.09M | 3.35M | 1.32M | 764.00K | 462.00K | 1.42M | 50.00K | 5.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.55M | 2.67M | 1.91M | 2.17M | 1.86M | 1.54M | 6.90M | 38.75M | 45.60M | 46.83M | 38.65M | 46.06M | 43.82M | 43.32M | 32.13M | 5.31M | 22.43M | 12.53M | 12.53M | 3.56M | 0.00 | 9.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 82.66M | 67.86M | 57.84M | 51.81M | 54.53M | 54.97M | 52.18M | 58.43M | 44.88M | 41.41M | 29.21M | 29.98M | 26.99M | 24.49M | 16.69M | 13.07M | 12.96M | 7.41M | 8.19M | 13.91M | 17.69M | 23.21M | 47.67M | 34.84M | 24.70M | 17.80M | 10.40M | 6.50M | 2.60M | 900.00K | 400.00K |
| EBITDA | 919.43M | 599.64M | 630.20M | -178.24M | 475.66M | 209.84M | -253.21M | 204.57M | 98.04M | 39.96M | -14.99M | 31.89M | -115.73M | 35.96M | -123.08M | -146.22M | -72.32M | -76.86M | -92.59M | -132.06M | -149.30M | -110.52M | -17.03M | -27.75M | -2.30M | 30.00M | 14.00M | -2.40M | -8.10M | -11.20M | -4.50M |
| EBITDA Ratio | 24.88% | 18.60% | 20.47% | -8.14% | 21.95% | 9.95% | -14.23% | 15.09% | 7.66% | -0.28% | -4.16% | 0.64% | -151.59% | 10.62% | -1,076.54% | -3,736.80% | -211.16% | -268.72% | -1,185.22% | -949.10% | -103.41% | -36.62% | 54.07% | -13.63% | 2.10% | 26.93% | 15.84% | 3.11% | -78.69% | -5,950.00% | -1,566.67% |
| Operating Income | 620.53M | 579.44M | 585.78M | -240.29M | 402.01M | 129.22M | -243.73M | 145.00M | 50.65M | -4.80M | -16.10M | 1.15M | -143.18M | 14.05M | -139.77M | -159.29M | -85.28M | -76.86M | -100.78M | -148.85M | -149.30M | -97.91M | -64.70M | -62.59M | -27.00M | 12.20M | 7.40M | -5.90M | -11.00M | -12.10M | -4.90M |
| Operating Income Ratio | 16.79% | 17.07% | 19.62% | -9.01% | 18.62% | 6.87% | -15.87% | 13.11% | 6.72% | -0.94% | -4.54% | 0.39% | -151.59% | 8.27% | -1,508.56% | -4,064.53% | -247.62% | -278.06% | -1,284.53% | -1,052.26% | -317.03% | -96.35% | -29.51% | -32.24% | -17.20% | 9.05% | 8.37% | -14.11% | -90.16% | -6,050.00% | -1,633.33% |
| Total Other Income/Expenses | 213.69M | -50.32M | -15.33M | 31.46M | 84.79M | -13.88M | -68.90M | -37.59M | -43.10M | -43.74M | -66.75M | -45.29M | -43.36M | -45.90M | -72.10M | -19.63M | -1.60M | 2.70M | -3.13M | -14.36M | -16.69M | 2.70M | -122.27M | 29.92M | -600.00K | -6.30M | 0.00 | 2.30M | 1.10M | 700.00K | 200.00K |
| Income Before Tax | 834.22M | 529.12M | 570.44M | -232.22M | 486.79M | 115.35M | -312.29M | 107.40M | 7.56M | -48.55M | -82.85M | -44.15M | -186.54M | -31.85M | -211.87M | -178.92M | -86.88M | -74.17M | -103.91M | -163.21M | -165.99M | -135.77M | -186.97M | -32.67M | -27.60M | 5.90M | 10.90M | -6.60M | -9.80M | -11.40M | -4.70M |
| Income Before Tax Ratio | 22.57% | 15.59% | 19.10% | -8.71% | 22.55% | 6.13% | -20.33% | 9.71% | 1.00% | -9.49% | -23.34% | -14.86% | -197.49% | -18.75% | -2,286.78% | -4,565.45% | -252.27% | -268.30% | -1,324.36% | -1,153.76% | -352.47% | -133.61% | -85.27% | -16.82% | -17.58% | 4.38% | 12.33% | -15.79% | -80.33% | -5,700.00% | -1,566.67% |
| Income Tax Expense | 236.62M | 188.46M | -378.14M | 63.48M | 39.89M | 5.85M | 852.00K | 3.18M | 1.03M | -66.00K | 299.00K | 174.00K | -26.99M | 21.41M | 55.41M | 19.63M | 1.60M | -552.00K | -552.00K | 453.00K | 477.00K | 1.12M | 930.00K | 205.00K | -800.00K | 2.40M | 500.00K | 900.00K | -900.00K | -600.00K | 0.00 |
| Net Income | 597.60M | 340.66M | 948.58M | -295.70M | 446.91M | 109.49M | -313.14M | 104.22M | 6.53M | -48.48M | -83.15M | -44.32M | -186.54M | -31.85M | -211.87M | -178.92M | -86.88M | -74.17M | -103.04M | -164.82M | -166.46M | -136.89M | -183.24M | -29.74M | -26.80M | 3.50M | 10.40M | -6.80M | -10.10M | -11.50M | -4.90M |
| Net Income Ratio | 16.17% | 10.04% | 31.76% | -11.09% | 20.70% | 5.82% | -20.38% | 9.43% | 0.87% | -9.48% | -23.43% | -14.92% | -197.49% | -18.75% | -2,286.78% | -4,565.45% | -252.27% | -268.30% | -1,313.32% | -1,165.11% | -353.48% | -134.71% | -83.57% | -15.31% | -17.07% | 2.60% | 11.76% | -16.27% | -82.79% | -5,750.00% | -1,633.33% |
| EPS | 2.67 | 1.53 | 4.30 | -1.36 | 2.08 | 0.52 | -1.53 | 0.55 | 0.04 | -0.29 | -0.56 | -0.34 | -1.49 | -0.26 | -2.06 | -1.99 | -1.03 | -0.89 | -1.24 | -2.21 | -2.33 | -2.03 | -2.77 | -0.47 | -0.48 | 0.07 | 0.14 | -0.17 | -0.31 | -0.41 | -0.19 |
| EPS Diluted | 2.65 | 1.52 | 4.27 | -1.36 | 2.05 | 0.51 | -1.53 | 0.54 | 0.03 | -0.29 | -0.56 | -0.34 | -1.49 | -0.26 | -2.06 | -1.99 | -1.03 | -0.89 | -1.24 | -2.21 | -2.33 | -2.03 | -2.77 | -0.47 | -0.48 | 0.06 | 0.13 | -0.17 | -0.31 | -0.41 | -0.19 |
| Weighted Avg Shares Out | 223.63M | 222.00M | 220.43M | 218.07M | 214.91M | 212.38M | 204.58M | 187.87M | 179.60M | 167.18M | 148.40M | 129.75M | 125.36M | 121.63M | 102.94M | 89.79M | 84.19M | 83.80M | 83.32M | 74.56M | 71.37M | 67.40M | 66.19M | 63.21M | 56.28M | 53.84M | 49.29M | 40.00M | 33.00M | 28.05M | 25.58M |
| Weighted Avg Shares Out (Dil) | 225.93M | 223.96M | 222.07M | 218.07M | 217.66M | 215.64M | 204.58M | 194.13M | 187.30M | 167.95M | 148.40M | 129.75M | 125.36M | 121.63M | 102.94M | 89.79M | 84.19M | 83.80M | 83.32M | 74.56M | 71.37M | 67.40M | 66.19M | 63.21M | 56.28M | 57.80M | 53.08M | 40.00M | 33.00M | 28.05M | 25.58M |
ATTENTION Incyte Corporation Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced...
INCY STOCK ALERT: Levi & Korsinsky Notifies Incyte Corporation Investors of an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced...
Incyte Corporation Being Investigated on Behalf of Incyte Corporation Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced...
Lost Money on Incyte Corporation(INCY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced...
Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Incyte Announces Updated Presentation Time for Upcoming Investor Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will now present at Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 8:00 a.m. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be...
INCY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Incyte Corporation investment
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced...
Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH24--Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting.
ATTENTION Incyte Corporation Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced...
INCY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Incyte Corporation investment
NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced...
Source: https://incomestatements.info
Category: Stock Reports